Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
WATERTOWN, Mass. - Vigil Neuroscience, Inc. (NASDAQ:VIGL), a biotech firm focusing on neurodegenerative diseases with a current market capitalization of $78.4 million, announced the progression of its Alzheimer’s disease (AD) drug candidate, VG-3927, to Phase 2 clinical trials. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 2.95, though it faces significant cash burn challenges typical of early-stage biotech firms. The announcement was made following presentations at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria.
The company’s lead clinical candidate, VG-3927, is an oral small molecule TREM2 agonist designed to engage microglia, the brain’s immune cells, to counteract multiple pathologies associated with AD. Preclinical studies have shown that VG-3927 enhances microglial uptake of amyloid-beta and Tau, proteins implicated in the disease’s progression.
Phase 1 trial results, involving 115 participants, demonstrated VG-3927’s favorable safety and tolerability profile, with no serious adverse events reported. All treatment-related adverse events were mild or moderate and self-resolving. The drug also exhibited a predictable and dose-dependent pharmacokinetic profile, supporting once-daily oral dosing.
VG-3927’s high central nervous system (CNS) penetrance was confirmed with an estimated cerebral spinal fluid to unbound plasma ratio of 0.91. Additionally, the trial’s pharmacodynamic data showed a reduction in soluble TREM2 (sTREM2) levels, consistent across healthy volunteers, elderly participants, and a cohort of AD patients. These findings support the drug’s development across various genetic risk factors for AD.
Based on these results, Vigil Neuroscience plans to initiate Phase 2 development of VG-3927 in the third quarter of 2025. The company’s goal is to offer a new therapeutic option for individuals affected by AD that may improve treatment outcomes. While the stock has experienced a significant decline of over 50% in the past six months, InvestingPro analysis suggests the company is currently undervalued, with analyst price targets ranging from $11 to $22 per share.
VG-3927’s differentiating factors include its oral bioavailability and its dual mechanism as an agonist and positive allosteric modulator. Unlike antibody TREM2 agonists, VG-3927 does not bind to sTREM2, potentially increasing its therapeutic efficacy.
This news is based on a press release statement from Vigil Neuroscience. The company is committed to advancing precision-based therapies for neurodegenerative diseases, with VG-3927 being a central part of their portfolio for common conditions like AD. With its next earnings report due on May 7, 2025, investors seeking deeper insights into Vigil’s financial health and growth prospects can access additional analysis and 8 more exclusive ProTips through InvestingPro.
In other recent news, Vigil Neuroscience reported an adjusted loss per share of $0.57 for Q4 2024, falling short of analyst estimates by $0.03. The company concluded 2024 with $97.8 million in cash and equivalents, which it projects will support operations into 2026. Vigil Neuroscience is advancing its drug candidate VG-3927 for Alzheimer’s disease, having announced positive Phase 1 trial results. The drug demonstrated a favorable safety profile and achieved a significant reduction in a key biomarker, prompting plans to proceed with a Phase 2 trial in Q3 2025. CEO Ivana Magovčević-Liebisch expressed confidence in the progress of their TREM2 programs, including VG-3927 and iluzanebart.
Additionally, H.C. Wainwright analyst Andrew Fein lowered the price target for Vigil Neuroscience from $17 to $14 but maintained a Buy rating. This adjustment reflects a reassessment of the company’s operational expenses beyond 2025. Vigil is also working on iluzanebart for ALSP, with final Phase 2 data expected in Q2 2025 and a potential accelerated approval pathway being explored. These developments indicate significant activity in Vigil’s pipeline, with investors closely watching upcoming trial results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.